Researchers at Johns Hopkins report that a novel analysis of more than a thousand patients adds to evidence that hospitalization, critical illness and major infection may diminish brain structures that are most commonly affected by Alzheimer’s disease.
AFA applauds Congress and the Administration for recognizing the importance of putting Alzheimer’s front and center and doing so at an unprecedented level. AFA expresses much gratitude on behalf of all of our nation’s families to members of the Senate and House Appropriations Committee who worked so hard to accomplish this significant development
Rutgers researchers discover possible cause for Alzheimer’s and Traumatic Brain Injury. The new mechanism may have also led to the discovery of an effective treatment.
Las células zombi son aquellas que no pueden morir, pero que tampoco son capaces de realizar las funciones de una célula normal. Estas células zombi, o células senescentes, participan en varias enfermedades relacionadas.
Kim Innes, an epidemiology professor from the West Virginia University School of Public Health, and her team are studying the potential benefits of a simple meditation or music listening practice for improving memory and cognitive functioning, as well as mood, sleep and quality of life in adults with subjective cognitive decline, or SCD.
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have developed new single-cell approaches wedded to machine learning. This has revealed thousands of previously unknown DNA changes arising during prenatal life in the developing mouse brain. The study published today in PNAS.
During aging, loss of vision and cognition often coincide. In a new study, researchers funded by the National Eye Institute (NEI) and National Institute on Aging (NIA) have found that vision loss precedes loss of mental capacity. The findings suggest that maintaining eye health could help protect cognition in older adults.
僵尸细胞是那些不能死亡但同样无法执行正常细胞功能的细胞。 这些僵尸或衰老细胞涉及许多与年龄有关的疾病。Mayo Clinic的研究人员在《自然》杂志上发表的研究信件中扩大了僵尸细胞的名单。
Nearly 200 academic and industry researchers gathered this week to share updates on preclinical and clinical-stage Alzheimer's disease research at the 19th International Conference on Alzheimer's Drug Discovery. The two-day conference, organized by the Alzheimer's Drug Discovery Foundation (ADDF), focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs to treat Alzheimer's disease (AD) and related dementias, as well as the need for new biomarkers.
روتشستر، مينيسوتا - خلايا الزومبي هي تلك الخلايا التي لا تموت ولكن لا يمكنها أداء وظائف الخلية الطبيعية بنفس الكفاءة. وتساهم تلك الخلايا الزومبية - أو الخلايا الشائخة - في عدد من الأمراض المرتبطة بعمر الإنسان. وفي رسالة جديدة نُشرت في مجلة الطبيعة "Nature"، استعرض باحثو Mayo Clinic تلك القائمة باستفاضة.
As células zumbis são células que não morrem, mas que também não realizam funções celulares normais. Essas células senescentes, ou zumbis, estão relacionadas a algumas doenças decorrentes da idade. Em um novo artigo publicado na Nature, os pesquisadores da Mayo Clinic ampliaram essa lista.
People who participate in light to moderate physical activity, such as walking at least four hours a week or swimming two to three hours a week, may have less severe strokes than people who are physically inactive, according to a study published in the September 19, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.
ROCHESTER, Minn. — Zombie cells are the ones that can't die but are equally unable to perform the functions of a normal cell. These zombie, or senescent, cells are implicated in a number of age-related diseases. And with a new letter in Nature, Mayo Clinic researchers have expanded that list.
Image classification models trained on brain MRIs of dementia patients could help support early diagnosis for more effective treatment.
Astrocytes' important role in brain function suggests they are also involved in disease. Now, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified an astrocyte subpopulation as the dominant cell type to spring into action in vivo (in a living organism) in a neuroinflammatory disease setting. The study published today in eNeuro.
A behavioral treatment that helps adults set goals toward a more active social, cognitive, and physical lifestyle can reduce memory decline, in a randomized controlled trial.
While many think of the progression of Alzheimer’s mostly as a cognitive process, the mind and body are inherently linked. A new three-year project at Michigan Technological University, funded by the National Institutes of Health, explores that link.
A West Virginia University graduate student is studying how certain cells affect the development of this part of the brain, and therefore, how they could affect how quickly and accurately the brain processes sounds.
Analysis of data captured during a long-term study of aging adults shows that those who report being very sleepy during the day were nearly three times more likely than those who didn’t to have brain deposits of beta amyloid, a protein that’s a hallmark for Alzheimer’s disease, years later.
Scientists seek to better understand protein folding to cure misfolding diseases, but this incredibly complex process requires sophisticated algorithms to identify the folding mechanisms. Computational biophysicists have proposed a new way to identify the most crucial factors for protein folding. They demonstrated the short simulation time of their approach on a small but intriguing protein, “GB1 beta-hairpin,” in The Journal of Chemical Physics.
Aliviado—which means “relief” in Portuguese—aims to provide relief to people living with dementia and their caregivers through helping home health and hospice agencies provide high-quality, compassionate care.
Tiny protein structures called amyloids are key to understanding certain devastating age-related diseases. Aggregates, or sticky clumped-up amyloids, form plaques in the brain, and are the main culprits in the progression of Alzheimer’s and Huntington’s diseases.Amyloids are so tiny that they can’t be visualized using conventional microscopic techniques.
Researchers at the University of Florida have discovered that a modified version of an important immune cell protein could be used to treat Alzheimer’s disease. The study, which will be published August 29 in the Journal of Experimental Medicine, reveals that soluble versions of a protein called TLR5 can reduce the buildup of amyloid plaques in the brains of Alzheimer’s disease model mice and prevent the toxic peptide that forms these plaques from killing neurons.
Using technology similar to what is found in many eye doctors’ offices, researchers at Washington University School of Medicine in St. Louis have detected evidence suggesting Alzheimer’s in older patients who had no symptoms of the disease.
Dthera™ Sciences (OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ.
A new study, authored by Anthony Bardo and Scott Lynch, examines "cognitive life expectancy." What exactly does that term mean? Bardo, an assistant professor of sociology at the University of Kentucky, describes "cognitive life expectancy" as how long older adults live with good versus declining brain health.
Tulane University research could shed light on the molecular details of Alzheimer’s and Parkinson’s.
A University of Adelaide-led team of scientists has suggested a potential link between iron in our cells and the rare gene mutations that cause Alzheimer’s disease, which could provide new avenues for future research.
Scientists at Johns Hopkins Bloomberg School of Public Health have developed a powerful method for characterizing the broad patterns of genetic contributions to traits and diseases.
Johns Hopkins Medicine researchers say a study designed to see if reducing the amount of anesthesia reduces the risk of postoperative delirium in older patients surprisingly found that lighter sedation failed to do so in severely ill people undergoing hip fracture repair.
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, today announced the launch of Magnolia Neurosciences Corporation, a company developing a new class of neuroprotective medicines, with $31 million in Series A funding. The company will develop novel therapeutics based on discoveries made by researchers in MD Anderson’s Therapeutics Discovery division, including the Institute for Applied Cancer Science (IACS) and the Neurodegeneration Consortium (NDC).
Reduced levels of a chaperone protein might have implications for the development of Parkinson’s disease and Lewy body dementia, according to new research from UAB. Chaperone protein 14-3-3 could lead to misfolding and spread of alpha-synuclein.
• Older adults who initiate dialysis for kidney failure face a higher likelihood of being diagnosed with dementia and Alzheimer’s disease. • Certain risk factors were linked this higher risk. • Older hemodialysis patients with a diagnosis of dementia or Alzheimer’s disease had a high risk of early death.
Older kidney disease patients who are sick enough to require the blood-filtering treatment known as dialysis are at high risk of dementia, including Alzheimer’s disease, according to a study led by scientists at Johns Hopkins Bloomberg School of Public Health.
A clinical trial being conducted at Georgetown explores if nicotine can slow or stop memory loss in people experiencing mild memory problems, or mild cognitive impairment (MCI).
There is new hope for the treatment of Alzheimer’s and other neurological diseases following a ground-breaking discovery made by an Australian-Chinese research collaboration.
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio—part of The Harrington Project for Discovery & Development—has announced three new scholars in collaboration with its partners Foundation Fighting Blindness (FFB) and Alzheimer’s Drug Discovery Foundation (ADDF). Harrington Discovery Institute collaborates with FFB on the Gund-Harrington Award to accelerate therapies for retinal degenerative diseases and ADDF to advance the development of drugs to prevent and treat Alzheimer’s disease.
"In humans, being able to tweak levels of TTR degradation could act as a means of stopping TTR toxicity."
The process, discovered in the axons of neurons, is implicated in Alzheimer’s, amyotrophic lateral sclerosis, traumatic brain injury and other diseases or injuries to the nervous system.
Johns Hopkins Medicine scientists say they have found new evidence in lab-grown mouse brain cells, called astrocytes, that one root of Alzheimer’s disease may be a simple imbalance in acid-alkaline—or pH—chemistry inside endosomes, the nutrient and chemical cargo shuttles in cells.
More than 90 percent of people caring for a family member with dementia experience poor sleep, according to new research by the University at Buffalo School of Nursing.
Rutgers researchers will benefit from a $250,000 grant from the Gillson Longenbaugh Foundation to help expand the team’s work on neural stem cell interactions and developing antibody therapeutics for cancer treatment.
Glaucoma Research Foundation, a national non-profit organization dedicated to finding a cure for glaucoma, today announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also be applicable to other neurodegenerative diseases, including Alzheimer's disease.
Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fujirebio” or “the Company”) announced today that it has entered into an agreement with US-based Janssen Pharmaceuticals, Inc. (hereinafter “Janssen”) to develop and commercialize an AMYLOID β 42/40 RATIO assay.
A small population of brain cells called "mossy cells" deep in a memory-making region of the brain controls the production of new neurons and may have a role in common brain disorders, according to a study from scientists at the University of North Carolina School of Medicine.
People who feel faint, dizzy or lightheaded when standing up may be experiencing a sudden drop in blood pressure called orthostatic hypotension. Now a new study says middle-aged people who experience such a drop may have a greater risk of developing dementia or stroke decades later. The study is published in the July 25, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Preliminary results of the SPRINT MIND trial found that lowering one’s systolic blood pressure to 120 mm Hg reduces the risk of mild cognitive impairment and dementia.
The results of the first ever clinical trial of focused ultrasound to open the blood-brain barrier (BBB) in patients with Alzheimer’s disease were published today in Nature Communications and also presented at the Alzheimer’s Association International Conference (AAIC) in Chicago, Illinois. The pilot trial demonstrated the feasibility and preliminary safety of focally, reversibly and repetitively opening the BBB.
In a study published online July 25 in the journal Nature, University of California San Diego School of Medicine researchers identified a signaling pathway that activates the NLRP3 inflammasome implicated in several severe chronic inflammatory disorders.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right